: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook
: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC)
AI responses may include mistakes. For financial advice, consult a professional. Learn more
: On August 22, 2024, KARL STORZ finalized its acquisition of Asensus Surgical.
: Under the terms of the merger agreement, all outstanding shares of ASXC were acquired for $0.35 per share in cash .
: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout.
: The symbol transitioned from TRXC to ASXC as part of this corporate shift.
Since the company is now , it is not possible to buy or sell shares on public markets.
: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook
: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC)
AI responses may include mistakes. For financial advice, consult a professional. Learn more
: On August 22, 2024, KARL STORZ finalized its acquisition of Asensus Surgical.
: Under the terms of the merger agreement, all outstanding shares of ASXC were acquired for $0.35 per share in cash .
: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout.
: The symbol transitioned from TRXC to ASXC as part of this corporate shift.
Since the company is now , it is not possible to buy or sell shares on public markets.
